Abstract
Early detection of potential side effects (SE) is a critical and challenging task for drug discovery and patient care. In-vitro or in-vivo approach to detect potential SEs is not scalable for many drug candidates during the preclinical stage. Recent advances in explainable machine learning may facilitate detecting potential SEs of new drugs before market release and elucidating the critical mechanism of biological actions. Here, we leverage multi-modal interactions among molecules to develop a biologically informed graph-based SE prediction model, called HHAN-DSI. HHAN-DSI predicted frequent and even uncommon SEs of the unseen drug with higher or comparable accuracy against benchmark methods. When applying HHAN-DSI to the central nervous system, the organs with the largest number of SEs, the model revealed diverse psychiatric medications’ previously unknown but probable SEs, together with the potential mechanisms of actions through a network of genes, biological functions, drugs, and SEs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
XJ is CPRIT Scholar in Cancer Research (RR180012), and he was supported in part by Christopher Sarofim Family Professorship, UT Stars award, UTHealth startup, the National Institute of Health (NIH) under award number R01AG066749 and U01TR002062. YK is partly supported by R01AG066749 and RR180012.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Contributing authors E-mail: Tongtong.Huang{at}uth.tmc.edu; Kohong.Lin{at}uth.tmc.edu; rodrigo.machadovieira{at}uth.tmc.edu; jair.c.soares{at}uth.tmc.edu; Xiaoqian.Jiang{at}uth.tmc.edu;
Data Availability
Data availability are as follows: Zhang's side effects (https://doi.org/10.1186/s12859-015-0774-y), package-insert side effects (SIDER 4.1, http://sideeffects.embl.de/), post-marketing side effects (OFFSIDES, https://tatonettilab.org/offsides/), human protein-protein interaction network that contails physical interactions (BioSNAP, https://snap.stanford.edu/biodata/datasets/10000/10000-PP-Pathways.html), Gene Ontology's Biological Process97 (https://github.com/snap-stanford/multiscale-interactome), drug target data (DrugBank, https://go.drugbank.com/), gene-SE interactions (PharmGKB variant annotations, https://www.pharmgkb.org/downloads), SE-SE categorial similarities98 (Main or High-Level Term Medical Dictionary for MedDRA terminology classification for each side effect term). The curated CNS-related dataset is publicly available at https://github.com/th8930/HHAN-DSI.
